Maybe AH

SRM end of day run - close at 10?

Nice premarket move - tapping 15.5

10Q
Blue Dolphin Energy Co., a company engaged in refinery operations and tolling and terminaling, has released its Form 10-Q report for the third quarter. The report outlines significant financial and operational challenges faced by the company, including decreased revenues and profitability, as well as strategic initiatives aimed at navigating macroeconomic uncertainties.

Financial Highlights

Total Revenue: $83.7 million, reflecting a decrease from $91.0 million in the prior year period due to less favorable refining margins and lower sales volumes.
Gross Profit: $6.1 million, calculated as Total Revenue minus Total Cost of Goods Sold ($83.7 million - $77.6 million), indicating a decline in profitability compared to the previous year.
Income from Operations: $4.3 million, down from $9.8 million in the prior year period, primarily due to increased general and administrative expenses and less favorable refining margins.
Net Income: $2.2 million, a significant decrease from $6.6 million in the prior year period, impacted by lower operating income and higher interest expenses.
Basic and Diluted EPS: $0.15, compared to $0.44 in the prior year period, reflecting the decrease in net income.
Business Highlights

Revenue Segments: The company operates in two main segments: refinery operations and tolling and terminaling. Refinery operations generated $82,868,000 in revenue, while tolling and terminaling contributed $1,391,000, with an intercompany elimination of $567,000.
Sales Units: The refinery operations segment processed light sweet crude oil, with a capacity of 15,000 barrels per day. Inventory levels increased due to unfavorable product pricing and limited export opportunities.
Operational Challenges: The company faced less favorable refining margins and lower sales volumes compared to the previous year, impacting net income.
Future Outlook: Management anticipates continued challenges due to macroeconomic uncertainties, including inflation, interest rates, and geopolitical tensions. The company is focused on optimizing its asset base, improving operational efficiencies, and seizing market opportunities.
Business Strategy: The strategic objectives include maintaining safe operations, enhancing health, safety, and environmental systems, reducing variable costs, increasing throughput capacity, and leveraging existing infrastructure for renewable energy projects.

we had quite a good first day on the Nasdaq , we even made a high of 20.89 premarket. Today we have again some premarket volume and last price is 13.35.

premarket volume on Nasdaq current price premarket 15.5

a reverse merger is on it's way - looking good

i know i know 😑

this selloff is a bit drastic - reverse split is not so bad if this enables them to uplist to Nasdaq - so why the sell off? of course they should not increase the AS/OS

ACON nice move 😊

wow what just happened?

XPON ready for move up

FLYE continues his move - no watch

Looking good at opening

CMND watching for a move up after the excellent news

BAOS moving PM - wonder why

what's up with OGEN?

yes it seems...wondering what's happening

ORIS - what's going on?

Looks like the deal with HiTron is a done deal...what's next...

Wow what a move...what 's the target? 

NLSP wow

NLSP - moving PM

AGRI moving

page not found

SCNI nice move PM

SMFL - volume coming in

BJDX - not sure where it's heading

NLSP Announces Publication of New Patent Application for Next-Gen Dual Non-Sulfonamide Orexin Receptor Agonists (DOXA)

NLS Pharmaceutics Announces Publication of New Patent Application for Next-Gen Dual Non-Sulfonamide Orexin Receptor Agonists (DOXA)

ONMD what a beast

BNED halted

MBIO next mover

AKTS ~ huge PM mover

EDBL - what an unpredictable stock (yesterday almost at 10 PM, now almost at 3 PM)

EDBL nice move PM

HARRISON, NY - (NewMediaWire) - May 16, 2024 - Metawells Oil & Gas Inc. (the "Company" or "KOSK") is pleased to announce that it has entered into a definitive agreement dated May 14, 2024 (the "Definitive") to merge with Global Oil & Gas Recovery Corp. an arm's length privately held company ("GlobalOG") incorporated in the state of Delaware.

The transaction is structured as a shares exchange and KOSK will acquire all the issued and outstanding capital interest or shareholdings of Global, in exchange with KOSK authorized but unissued common stock. The agreement includes a series of representations and warranties by both parties and conditions that precedent the corporate action. Global is currently a private company and exists in good standing under the laws of the State of Delaware.

KOSK President Ronald Minsky states that, "This merger with Global will be extremely beneficial for KOSK shareholders as Global brings in cutting edge technology for the recuperation of oil and gas from abandoned and zombie oil fields in the U.S. and Canada." Global Oil and Gas Recovery Corporation CEO Richard Cindric states, "Global has been looking for the proper partner to take our business to new heights with our cutting-edge technology. We look forward to the days ahead to putting our company on the map as a big player in the oil and gas recovery business."

About Metawells Oil & Gas Inc.

Metawells Oil & Gas Inc. is a holding company founded in the State of Nevada and engaged in two sectors, the energy sector and the sector of technology. The Company is set to forge strategic collaborations and develop both business segments to accelerate the company growth. The company is currently working on its strategic business plan to become an oil producer, focused on the multi-zone development and Enhanced Oil Recovery ("EOR") of "extreme shallow" medium gravity oil.

www.metawellsinc.com

Omega Therapeutics Presents New Preclinical Data at ASGCT 2024 Demonstrating Tunable and Durable Upregulation of Gene Expression with Epigenomic Controllers May 08 2024 - 7:00AM

Omega Therapeutics, Inc. (Nasdaq: OMGA) (“Omega”), a clinical-stage biotechnology company pioneering the development of a new class of programmable epigenomic mRNA medicines, today announced the presentation of new preclinical data demonstrating durable and tunable bidirectional regulation of gene expression in cellular models at the pre-transcriptional level at the American Society of Gene and Cell Therapy (ASGCT) 27th Annual Meeting, taking place in Baltimore, Maryland, May 7 – 11.
“These exciting new data underscore the versatile capabilities and power of our OMEGA platform,” said Thomas McCauley, Ph.D., Chief Scientific Officer of Omega Therapeutics. “We have demonstrated preclinically that we can prospectively engineer epigenomic controllers to predictably and durably upregulate gene expression across a diverse range of gene types, including turning on inactivated genes, augmenting the expression of genes with low baseline expression levels, and leveraging existing genomic regulatory processes to boost expression. These capabilities unlock a wide spectrum of possibilities to apply precision epigenomic control as a novel therapeutic modality to meaningfully address key drivers of many diseases.”

News: Plus Therapeutics Announces Private Placement Financing of up to $18 Million
https://www.globenewswire.com/news-release/2024/05/06/2875716/0/en/Plus-Therapeutics-Announces-Private-Placement-Financing-of-up-to-18-Million.html

AWIN - what's behind the move? no news